Medical Policies
Please note the following changes will be implemented to the designated medical policies.
- Effective 02/09/2022, MetroPlusHealth is implementing MPS 339 (Urinary Biomarkers) and MPS 340 (Unspecified Polymerase Chain Reaction Testing). We will not cover urinary biomarkers (88120, 88121) as a screening tool for bladder malignancy. We will cover unspecified polymerase chain reaction testing (87798) up to 2 units per DOS prior to requiring additional information.
- Effective 6/3/2021, MetroPlusHealth revised medical policy UM-MP231 Allergy Testing. We will only cover allergy testing when it is performed by board certified or residency trained Allergists/Immunologists or Dermatologists.
MetroPlus Health Plan utilizes clinical review criteria based upon a review of currently available clinical information(including Change Healthcare InterQual guidelines, clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors).
MetroPlus Health Plan expressly reserves the right to revise these conclusions as clinical information changes and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by MetroPlus Health Plan, as some programs exclude coverage for services or supplies that MetroPlus Health Plan considers medically necessary. If there is a discrepancy between our internal established guidelines and a member’s benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members.
- UM-MP200 Abdominoplasty Panniculectomy
- UM-MP201 Automatic External Defibrillators
- UM-MP202 Bariatric Surgery
- UM-MP203 Blepharoplasty
- UM-MP206 Capsule Endoscopy Camera Pill
- UM-MP208 Gender Reassignment Surgery
- UM-MP214 Varicose Vein Treatment
- UM-MP216 Duchenne Muscular Dystrophy
- UM-MP218 Urine Drug Testing
- UM-MP219 Kymriah
- UM-MP221 Continuous Glucose Monitoring
- UM-MP222 Topical Oxygen Therapy
- UM-MP224 Exchange Transfusion for Sickle Cell Disease
- UM-MP228 MRgFUS
- UM-MP229 Pasteurized Human Donor Milk
- UM-MP230 Yescarta
- UM-MP231 Allergy Testing
- UM-MP232 Insulin Pump
- UM-MP233 Spinraza
- UM-MP234 Perinatal Care
- UM-MP235 Botulinumtoxin Therapy
- UM-MP237 Electromyography and Nerve Conduction Study
- UM-MP238 Erectile Sysfunction Treatment
- UM-MP239 Sleep Studies
- UM-MP240 Treatment for HIV Associated Facial Lipoatrophy
- UM-MP243 Medicare Supervised Exercise Therapy (SET) for PAD
- UM-MP244 Utilization Management Member Outreach
- UM-MP245 EM Reimbursement Policy
- UM-MP246 CardioMEMS
- UM-MP247 Whole Genome Sequencing
- UM-MP248 Gene Expression Profile Testing for Multiple Myeloma
- UM-MP249 Chemical Peels and Dermabrasion
- UM-MP251 Folic Acid Testing
- UM-MP252 Thyroid Testing Policy
- UM-MP253 Vitamin D Testing
- UM-MP254 Acupuncture
- UM-MP255 Amylase Testing
- UM-MP256 Helicobacter Pylori Testing
- UM-MP257 Acromegaly Part B Step Therapy
- UM-MP258 Alpha-1 Antitrypsin deficiency Part B Step Therapy
- UM-MP259 Medicare Autoimmune Drug Policy
- UM-MP261 Hematologic, Erythropoiesis Stimulating Agents (ESA) Part B Step Therapy
- UM-MP262 Hematologic, Neutropenia Colony Stimulating Factors LA Part B Step Therapy
- UM-MP263 Hematologic, Neutropenia Colony Stimulating Factors SA Part B Step Therapy
- UM-MP264 Lysosomal Storage Disorders Gaucher Disease Part B Step Therapy
- UM-MP265 Multiple Sclerosis (Infused) Part B Step Therapy
- UM-MP266 Osteoarthritis, Viscosupplements Part B Step Therapy
- UM-MP267 Prostate Cancer LHRH Agents Part B Step Therapy
- UM-MP268 Retinal Disorders Agents Part B Step Therapy
- UM-MP269 Medicare Rituximab Policy
- UM-MP270 Trastuzumab Part B Step Therapy
- UM-MP271 Infertility Services
- UM-MP 320 Eculizumab
- UM-MP321 Ocrelizumab
- UM-MP323 Synagis
- UM-MP324 HIV Resistance Testing
- UM-MP325 Outpatient Physical and Occupational Therapy
- UM-MP326 Spravato (Esketamine)
- UM-MP327 Aduhelm
- UM-MP328 Trogarzo
- UM-MP329 Medicare – Severe Asthma Drug Policy
- UM-MP330 Cabenuva
- UM-MP331 CHP – Multiple Sclerosis (Infused) Step Therapy
- UM-MP332 Cell-Free Fetal DNA Testing
- UM-MP333 Adaptive Behavior Treatment (ABT)
- UM-MP334 Abecma
- UM-MP335 Tecartus
- UM-MP336 Zoladex
- UM-MP337 High Tech Radiology Studies (CT-MRI-PET)
- UM-MP338 Complement Inhibitors
- UM-MP339 Urinary Biomarker
- UM-MP340 Unspecified Polymerase Chain Reaction Testing
- UM-MP341 Intradialytic Parental Nutrition
- UM-MP342 Outpatient Speech Therapy
- UM-MP343 Clinical Trial Coverage of Routine Care
- UM-MP344 Apretude (Cabotegravir)
- UM-MP345 Tecvayli (teclistamab-cqyv)
- UM-MP346 Carvykti (ciltacabtagene autoleucel)
- UM-MP347 Breyanzi (lisocabtagene maraleucel)
- UM-MP348 Bevacizumab Part B Step Therapy
- UM-MP Breast Reduction Mammoplasty
- UM-MP Obstructive Sleep Apnea (OSA)
- UM-MP Gene Expression Profile Testing for Multiple Myeloma
- UM-MP Gene Expression Profiling and Biomarker Testing for Breast Cancer
- UM-MP Genetic Testing for Colorectal Cancer Lynch Syndrome
- UM-MP Gynecomastia Surgery
Ready to Join Us?
Talk To Us About Questions Or Concerns
Monday–Saturday | 8 a.m.–8 p.m. (ET)
Sunday | 9 a.m. –5 p.m. (ET)
Already A Member?
Talk To Us About Any Questions or Concerns
Monday–Saturday | 8 a.m.–6 p.m. (ET)
Sunday | 9 a.m. –5 p.m. (ET)